Biogen's QALSODY (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP Seite 1
23.02.2024 - SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe1With QALSODY, Biogen has advanced the role of neurofilament in the development of new medicines for ALS, with the potential to ... Seite 1
United Kingdom Priya Singhal Head Of Development At Biogen European Union Committee For Medicinal Products Human Use European Commission
Source: wallstreet-online.de